The introduction of these anti-TNF-α therapies has profoundly transformed the management of moderate-to-severe IBD, leading to higher rates of clinical remission, mucosal healing, and a reduction in hospitalizations and surgeries [8]. This evidence concerns the gene TNF and inflammatory bowel disease.